Bradley J. Monk, MD, associate professor of obstetrics and gynecology at the College of Medicine – Phoenix, says in an interview that the future trajectory of antibody-drug conjugates in the treatment of patients with breast and gynecologic cancers will be shaped by findings from ongoing and upcoming tumor-agnostic trials that are investigating ADCs with various targets.